Our mission is to revolutionize healthcare by innovation and proximity to patients. As pioneers in transcatheter minimally invasive technology, we are developing and delivering a breakthrough tricuspid heart valve replacement system that brings hope and improves quality of life for those in need. Our commitment to excellence drives us to create a product that proves safety and efficacy for patients, and ease of use for healthcare professionals.
Location: France
Employees: 11-50
Total raised: $73.39M
Investors 2
| Date | Name | Website |
| 04.10.2022 | 415 Capita... | 415capital... |
| - | Andera Par... | anderapart... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.01.2026 | - | $23.39M | - |
| 25.07.2024 | Series D | $50M | - |
Mentions in press and media 7
| Date | Title | Description |
| 24.01.2026 | TRiCares: Up To €20 Million EIB Loan Secured To Advance Topaz Tricuspid Valve Replacement Trials | TRiCares SAS, a privately held medtech company developing a minimally invasive treatment for tricuspid regurgitation, said it has signed a loan agreement for up to €20 million in non-dilutive financing with the European Investment Bank, the... |
| 23.01.2026 | TRiCares To Receive €20M Loan From European Investment Bank | TRiCares, an Aschheim, Germany-based privately held company which specializes in the field of minimally invasive treatment of tricuspid regurgitation, raised €20M in non-dilutive funding. The amount came from the European Investment Bank (E... |
| 25.07.2024 | TRiCares Raises $50M in Series D Financing | TRiCares, a Paris, France- and Munich, Germany-based company which specializes in the field of minimally invasive treatment of tricuspid regurgitation, raised $50m in Series D funding. The round was led by a single, strategic investor. The ... |
| 25.07.2024 | Andera Partners’ portfolio company TRiCares secures $50 million in Series D Financing to Support Upcoming Clinical Milestones | Andera Partners, a leading European private equity player, announced today that its portfolio company TRiCares, a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, has raised $50 million (approx... |
| 09.07.2024 | Andera Partners co-leads a €63 million Series A round for Munich-based autoimmune biotech SciRhom | Andera Partners, a leading European private equity player, announced today that it is co-leading a € 63 million ($ 70 million) Series A financing for SciRhom, a biopharmaceutical company pioneering the development of first-in-class therapeu... |
| - | Tricares | “Home | TRiCares GmbH” |
| - | Tricares | “TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgiation.” |